Lobe Sciences Ltd

As of May 31, 2026, Lobe Sciences Ltd carries a market capitalization of 36.98M, placing it among publicly traded companies globally. Its enterprise value stands at 33.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, Lobe Sciences Ltd has 308.18M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Lobe Sciences Ltd maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.56, indicating elevated leverage, while an interest coverage ratio of -26.46 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended May 31, 2026. Return on assets (ROA) is negative at -85.26, reflecting losses generated across the asset base.

As of the close on August 6, 2026, Lobe Sciences Ltd's stock has gained approximately 27.27% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.06.

Over the twelve months ended May 31, 2026, Lobe Sciences Ltd generated - - in revenue and converted that into -5.77M in net income, yielding earnings per share of -0.03. EBITDA reached -6.63M, while operating income came in at -6.86M.

As of May 31, 2026, Lobe Sciences Ltd holds 5.21M in cash and equivalents against 338,401.00 in total debt, resulting in a net debt position of -1.17M. Total book value stands at 1.89M, with working capital of 3.20M providing operational flexibility.

Lobe Sciences Ltd produced -3.74M in operating cash flow over the twelve months ended May 31, 2026.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -12.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.72, meaning Lobe Sciences Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lobe Sciences Ltd's most recent stock split took place on June 21, 2022 with a 6:1 split ratio.

As of May 31, 2026, Lobe Sciences Ltd has an Altman Z-Score of -4.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.